Downtown San Francisco
San Francisco — Amongst all the chaos and frenetic activity that abounds big Pharma at JPM each year, I always look forward to hearing what the smaller biotechs are up to on days 3 and 4, as well as seeing how far some of them have progressed since our previous update on their pipeline agents.
In this latest update, there are definitely some companies we have been following longitudinally who are either poised for future success and growth… or due for a correction if the promising science doesn’t pan out as expected in the clinic.
Indeed one of those companies has already hit success and disappointment in the last two months alone, such is the roller coaster that is oncology R&D.
Please note that this is a rolling blog, which means that numerous updates are added throughout the day as new information becomes available.
To learn more from our oncology coverage and get a heads up on our latest commentary JPM annual meeting, subscribers can log-in or you can click to gain access to BSB Premium Content.
One of the pioneers and leading entrepreneurs in the development of personalised cancer vaccines is Professor Ugur Sahin.
In addition to being CEO of the privately-held biopharmaceutical company, BioNTech, he holds an academic appointment at the University of Mainz and is Managing Director of the translational research institute TRON.
This makes Mainz the perfect location for a cancer immunotherapy conference. It’s also where the Association for Cancer Immunotherapy (CIMT) is located. They were the local organisers of the 3rd annual CRI-CIMT-EATI-AACR cancer immunotherapy conference that we recently attended along with over 1400 people from around the world.
One of the underlying themes of the meeting and the posters was the development of personalised cancer vaccines, which is why we’re doing an extended mini-series based on interviews we did in Germany with leaders in the field.
Prof Sahin is a busy man, but we tracked him down in the poster hall. Here’s a brief excerpt from the impromptu interview he kindly gave to BSB.
Subscribers can log-in to read more of the latest thought leader interview or you can click to gain access to BSB Premium Content.